Education
About Us
Working with TipRanks
Follow Us
ProMIS Neurosciences (PMN)
NASDAQ:PMN
PMN Stock Chart & Stats
$8.12
-$0.04(-3.74%)
At close: 4:00 PM EST
$8.12
-$0.04(-3.74%)
Day’s Range― - ―
52-Week Range$6.27 - $39.75
Previous CloseN/A
Volume32.49K
Average Volume (3M)819.50K
Market Cap
$49.05M
Enterprise Value$17.22M
Total Cash (Recent Filing)$15.43M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.20
Next Earnings
Apr 06, 2026EPS Estimate
-4.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.00
Shares Outstanding2,152,397
10 Day Avg. Volume1,049,009
30 Day Avg. Volume819,497
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)1.49
Price to Sales (P/S)0.00
P/FCF Ratio-0.90
Enterprise Value/Market Cap0.35
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.59
Forecast
1Y Price Target
$29.33Price Target Upside261.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-6.31
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
PIPE Financing Extends RunwayA $75M PIPE materially extends operational runway into 2028, enabling the company to finance planned PMN310 development and regulatory milestones without immediate dilution pressures. This structural capital reduces near-term financing execution risk and lets management focus on clinical delivery.
Advancing PMN310 Clinical ProgramClear timing and funding for blinded 6‑ and 12‑month readouts provide concrete de‑risking milestones. Positive clinical outcomes would materially strengthen the company’s long‑term commercial prospects and validate its therapeutic approach, impacting strategic partnerships and future development priorities.
Regained Nasdaq Listing ComplianceRestoring Nasdaq compliance reduces structural listing risk and preserves access to public capital markets, institutional investors, and liquidity. Continued listing supports future financing and partnership opportunities, which is critical for capital‑intensive clinical development over multiple years.
Bears Say
Pre‑revenue With Sustained LossesBeing pre‑revenue and deeply loss‑making is a durable structural constraint: the business must convert clinical programs to approved products to become self‑sustaining. Until then the company depends on capital markets and partnerships, increasing execution risk if trials underperform or timelines slip.
High Operating Cash BurnConsistent ~‑$27M annual cash burn means the company cannot self‑fund development from operations. This persistent negative cash generation forces recurring external financings, which can dilute shareholders, constrain strategic optionality, and pressure prioritization of programs over the medium term.
Eroding Shareholders' EquityA meaningful decline in equity reflects cumulative losses and/or prior financings and signals limited internal capital buffers. With low equity and no operating cash inflows, the company remains exposed to dilution risk and may need further equity issuances to sustain development timelines and strategic initiatives.
ProMIS Neurosciences News
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $6.27 and its highest was $39.75 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $49.05M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Apr 06, 2026 which is in 33 days.
How were ProMIS Neurosciences’s earnings last quarter?
ProMIS Neurosciences released its earnings results on Nov 12, 2025. The company reported -$6 earnings per share for the quarter, beating the consensus estimate of -$7.25 by $1.25.
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -4.66.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 2,152,397 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
ProMIS Neurosciences reported an EPS of -$6 in its last earnings report, beating expectations of -$7.25. Following the earnings report the stock price went up 3.949%.
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ProMIS Neurosciences
ProMIS Neurosciences (PMN) is a biotechnology company focused on the discovery and development of precision therapeutics for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company utilizes its proprietary technology platform to selectively target misfolded proteins implicated in these diseases, aiming to develop disease-modifying treatments. ProMIS Neurosciences operates primarily in the biotechnology and pharmaceutical sectors, leveraging advanced scientific research to address unmet medical needs in neurodegenerative conditions.
PMN Stock 12 Month Forecast
Average Price Target
$29.33
▲(261.25% Upside)